{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:26:44Z","timestamp":1719883604712},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jpeds.2017.06.041","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T04:50:59Z","timestamp":1499921459000},"page":"31-39","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease"],"prefix":"10.1016","volume":"189","author":[{"given":"Jay","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2017.06.041_bib0010","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/art.10444","article-title":"Long-term outcome in patients with juvenile idiopathic arthritis","volume":"46","author":"Minden","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/berh.2002.0233","article-title":"Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis","volume":"16","author":"Oen","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0020","first-page":"579","article-title":"Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year follow-up","volume":"30","author":"Fantini","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0025","first-page":"394","article-title":"Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis","volume":"30","author":"Bowyer","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0030","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0040","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22087","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11926-013-0327-1","article-title":"Infectious complications in juvenile idiopathic arthritis","volume":"15","author":"Hurd","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","article-title":"Biologic-associated infections in pediatric rheumatology","volume":"17","author":"Horneff","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","article-title":"The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis","volume":"18","author":"Beukelman","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0060","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0065","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","article-title":"Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)","volume":"75","author":"Klotsche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0070","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","article-title":"Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis","volume":"65","author":"Beukelman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.38984","article-title":"Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial","volume":"67","author":"De Benedetti","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.130159","article-title":"Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors","volume":"41","author":"Shafferman","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rdc.2016.09.006","article-title":"Malignancy and the risks of biologic therapies: current status","volume":"43","author":"Seror","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0090","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1016\/j.vaccine.2010.03.080","article-title":"The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis","volume":"28","author":"Farmaki","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrrheum.2015.110","article-title":"Biosimilars in rheumatology: current perspectives and lessons learnt","volume":"11","author":"Dorner","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0105","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0110","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0115","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0125","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0140","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3899\/jrheum.120110","article-title":"Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry","volume":"39","author":"Beukelman","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0145","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0150","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","article-title":"Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis","volume":"50","author":"Papsdorf","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0160","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acr.22214","article-title":"Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs","volume":"66","author":"Simonini","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0165","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3899\/jrheum.121180","article-title":"Response of pediatric uveitis to tumor necrosis factor-alpha inhibitors","volume":"40","author":"Lerman","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0170","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0175","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0180","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11926-012-0239-5","article-title":"Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis","volume":"14","author":"Ferguson","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0185","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1542\/peds.2011-3788","article-title":"Pediatric chronic nonbacterial osteomyelitis","volume":"130","author":"Borzutzky","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0190","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0195","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","article-title":"Biologic therapy in primary systemic vasculitis of the young","volume":"48","author":"Eleftheriou","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0200","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"153","author":"Burns","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0205","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2165\/00003495-200969110-00002","article-title":"Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy","volume":"69","author":"Smith","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0210","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies","volume":"42","author":"Ai","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0215","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0220","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1546-0096-8-23","article-title":"Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?","volume":"8","author":"Cron","year":"2010","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0230","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0235","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","article-title":"Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study","volume":"62","author":"Simard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0240","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","article-title":"Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents","volume":"64","author":"Nordstrom","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0245","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0250","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0260","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0265","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","article-title":"Anakinra for systemic juvenile arthritis: the Rocky Mountain experience","volume":"15","author":"Zeft","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0275","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0280","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0285","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0290","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0295","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0300","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0305","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0310","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0315","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"10.1016\/j.jpeds.2017.06.041_bib0320","article-title":"Efficacy and safety of canakinumab in patients with periodic fever syndromes (colchicine-resistant FMF, HIDS\/MKD, and TRAPS): results from a phase 3, pivotal, umbrella trial [abstract]","volume":"68","author":"De Benedetti","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0325","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0330","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","article-title":"Macrophage activation syndrome","volume":"29","author":"Ravelli","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0335","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","article-title":"Macrophage activation syndrome in Kawasaki disease: more common than we thought?","volume":"44","author":"Wang","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0340","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","article-title":"Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"13","author":"Boom","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0350","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0355","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cct.2016.04.002","article-title":"Rationale and study design for a phase I\/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial)","volume":"48","author":"Tremoulet","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0365","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0370","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0375","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0380","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3899\/jrheum.151389","article-title":"Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis","volume":"43","author":"Birolo","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0385","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3899\/jrheum.140410","article-title":"Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis","volume":"42","author":"Tappeiner","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0390","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/13543784.2016.1154943","article-title":"Abatacept for the treatment of systemic lupus erythematosus","volume":"25","author":"Pimentel-Quiroz","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0395","doi-asserted-by":"crossref","first-page":"697525","DOI":"10.1155\/2013\/697525","article-title":"Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus","volume":"2013","author":"Ikeda","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0400","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0405","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0410","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0415","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0420","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.semarthrit.2016.07.012","article-title":"Tocilizumab treatment in childhood Takayasu arteritis: case series of four patients and systematic review of the literature","volume":"46","author":"Batu","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0425","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0430","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0435","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1535-7163.MCT-11-0972","article-title":"Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody","volume":"11","author":"Galeotti","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0440","doi-asserted-by":"crossref","first-page":"e000271","DOI":"10.1136\/rmdopen-2016-000271","article-title":"Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children","volume":"2","author":"Cabrera","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0445","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0450","article-title":"Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","author":"Schulert","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0455","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0460","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0465","article-title":"Variation in treatment of children hospitalized with antineutrophil cytoplasmic antibody-associated vasculitis in the United States","author":"James","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0470","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0475","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis","volume":"100","author":"Miserocchi","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0480","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0485","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0490","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0961203312471574","article-title":"Rituximab treatment in lupus nephritis\u2013where do we stand?","volume":"22","author":"Gunnarsson","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0495","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3899\/jrheum.140863","article-title":"Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases","volume":"42","author":"Tambralli","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1546-0096-12-3","article-title":"Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide","volume":"12","author":"Lehman","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0505","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00415-015-7781-9","article-title":"Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis","volume":"262","author":"Zekeridou","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0510","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rdc.2016.09.009","article-title":"The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management","volume":"43","author":"Molloy","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0520","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0525","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0530","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0535","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2017.06.041_bib0540","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347617308910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347617308910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T05:08:53Z","timestamp":1533272933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347617308910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":107,"alternative-id":["S0022347617308910"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.041","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}